PD-L1 / B7-H1 / CD274 Proteïne (ECD, mFc Tag)

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1 (PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

B7-H Protein; B7-H1 Protein; B7H1 Protein; hPD-L1 Protein; PD-L1 Protein; PDCD1L1 Protein; PDCD1LG1 Protein; PDL1 Protein

NP_054862.1

Human

Human

MFc-Tag

See Datasheet send with the product

< 1.0 EU per μg protein as determined by the LAL method.

≥ 95 % as determined by SDS-PAGE. ≥ 85 % as determined by SEC-HPLC.

1. Measured by its binding ability in a functional ELISA. Immobilized recombinant Human PD1-His at 10 μg/mL (100 μL/well) can bind human PD-L1 with a linear range of 1.28-20 μg/mL. 2. Labeled biotin to PD-L1 Protein, Human, Recombinant (ECD, Fc Tag) by a certain molar ratio; using the Octet RED System, the affinity constant (Kd) of PD-L1 Protein, Human, Recombinant (ECD, Fc Tag), Biotinylated bound to Atezolizumab was 0.1 nM. 3. CHO cells were transduced with human PD1 and subjected to flow cytometric analysis using recombinant human PDL1 protein (mouse IgG2a Fc tag) and a negative control protein. The cells were then stained with an FITC-conjugated anti-mouse IgG2a Fc antibody. Non-transduced CHO cells were used as a control. 4. Immobilized Recombinant Human PD-L1/B7-H1 Protein (ECD, mFc Tag) at 2 μg/mL (100 μL/well) can bind Recombinant Human PD-1 Protein (ECD, hFc Tag) the EC50 is 67-201 ng/mL. 5. Serial dilutions of Nivolumab were added into Recombinant Human PD-L1 / B7-H1 / CD274 Protein (ECD, mFc Tag), the Nivolumab derived Anti-PD1 Antibody, Human IgG4 can block the binding of 20 μg/mL of Recombinant Human PD-1 Protein (ECD), Biotinylated to Recombinant Human PD-L1 / B7-H1 / CD274 Protein (ECD, mFc Tag) . The IC50 is 278.7 ng/mL.

455

Lyophilized

20 mM Tris, 150 mM NaCl, 10 % Glycerol, pH 8.5.

See Datasheet

66 kDa (glycosylated)

Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

HEK 293 cells